Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last ¥2,872 JPY
Change Today -80.00 / -2.71%
Volume 33.0K
4552 On Other Exchanges
Symbol
Exchange
Berlin
Tokyo
As of 10:06 PM 07/27/15 All times are local (Market data is delayed by at least 15 minutes).

jcr pharmaceuticals co ltd (4552) Snapshot

Open
¥2,924
Previous Close
¥2,952
Day High
¥2,924
Day Low
¥2,866
52 Week High
07/22/15 - ¥3,250
52 Week Low
01/26/15 - ¥2,173
Market Cap
93.1B
Average Volume 10 Days
103.0K
EPS TTM
¥58.45
Shares Outstanding
32.4M
EX-Date
09/28/15
P/E TM
49.1x
Dividend
¥20.00
Dividend Yield
0.64%
Current Stock Chart for JCR PHARMACEUTICALS CO LTD (4552)

Related News

No related news articles were found.

jcr pharmaceuticals co ltd (4552) Related Businessweek News

No Related Businessweek News Found

jcr pharmaceuticals co ltd (4552) Details

JCR Pharmaceuticals Co., Ltd. engages in the research, development, manufacture, and sale of biopharmaceutical products based on recombinant DNA technologies primarily in Japan. Its product pipeline includes Follicle stimulating hormone, which is in Phase I/II clinical trials for the treatment of infertility; Alpha-galactosidase A that is in clinical trials to treat fabry and lysosomal storage diseases; and Iduronate-2-sulfatase, which is in the clinical trial in preparation stage for hunter syndrome. The company’s preclinical product pipeline comprises Darbopoietin Alfa to treat renal anemia, Glucocerebrosidase for gaucher disease, BBB-Penetrating Iduronate-2-sulfatase for the treatment of hunter syndrome, and Long-acting Somatropin for growth disorder treatment. It also develops cellular therapy products, including human mesenchymal stem cells for the treatment of graft-versus-host disease associated with hematopoietic stem cell transplantation. JCR Pharmaceuticals Co., Ltd. was founded in 1975 and is headquartered in Ashiya, Japan.

501 Employees
Last Reported Date: 06/24/15
Founded in 1975

jcr pharmaceuticals co ltd (4552) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

jcr pharmaceuticals co ltd (4552) Key Developments

JCR Pharmaceuticals Co., Ltd. and Eisai Co., Ltd. Announces Feasibility Study Agreement on Application of Blood-Brain-Barrier Penetration Technology to Discover New Treatments

JCR Pharmaceuticals Co., Ltd. and Eisai Co., Ltd. jointly announced that the two companies have concluded a feasibility study agreement on July 21, 2015, under which they will examine the possibility of applying JCR's proprietary blood-brain-barrier (BBB) penetration technology J-Brain Cargo to the discovery of new treatments. Under the terms of this agreement, JCR and Eisai will perform collaborative research using the J-Brain Cargo technology and certain pharmaceutical candidate compounds of Eisai's choice, aiming to create innovative pharmaceutical products primarily for diseases of the central nervous system. J-Brain Cargo enables delivery of target substances across the BBB through a certain receptor expressed on the surface of vascular endothelial cells. JCR studies confirmed BBB penetration of J-Brain Cargo combined target substance as 20 to 100 times the target substance alone. It is an innovative technology which will provide pharmaceutical compounds of small or large molecules with the capacity to pass through the BBB. A substantially large portion of the pharmaceutical injected intravenously should be able to reach inside the brain and confer its effect. Significant improvements are expected for neurological disorders for which little improvements have been possible. The conclusion of this agreement is expected to have a minor impact on consolidated financial results for the year ending March 31, 2016 for both companies.

JCR Pharmaceuticals Co., Ltd. to Report Q1, 2016 Results on Jul 21, 2015

JCR Pharmaceuticals Co., Ltd. announced that they will report Q1, 2016 results on Jul 21, 2015

JCR Pharmaceuticals Co., Ltd. and Sumitomo Dainippon Pharma Co., Ltd. Conclude Feasibility Study Agreement on Application of the Blood-Brain Barrier Penetration Technology in Psychiatry and Neurology Area

JCR Pharmaceuticals Co., Ltd. and Sumitomo Dainippon Pharma Co., Ltd. jointly announced that the two companies executed on June 17, 2015 a feasibility study agreement under which they will study the feasibility of applying JCR's proprietary blood-brain barrier (BBB) penetration technology "J-Brain Cargo" to discovery of new treatment in the psychiatry and neurology area. Under the terms of the agreement, JCR and Sumitomo Dainippon Pharma will perform collaborative research using the J-Brain Cargo technology and certain pharmaceutical candidate compounds of Sumitomo Dainippon Pharma's choice, with a view to creating innovative pharmaceutical products in psychiatry and neurology area, where high unmet medical needs exist. J-Brain Cargo enables delivery of target substances across the BBB through a certain receptor expressed on the surface of vascular endothelial cells. JCR study confirmed BBB penetration of J-Brain Cargo combined target substance as 20 to 100 times the target substance alone. It is an innovative technology which will provide pharmaceutical compounds of low to high molecules with the capacity to pass through the BBB. A substantially large portion of the pharmaceutical injected intravenously should be able to reach inside the brain and show its efficacy. Significant improvements are expected for psychiatric or neurological disorders for which little improvements have been possible. Financial impacts of the conclusion of the agreement is minor on the consolidated performance for the year ending on March 31, 2016 of either company.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4552:JP ¥2,872.00 JPY -80.00

4552 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4552.
View Industry Companies
 

Industry Analysis

4552

Industry Average

Valuation 4552 Industry Range
Price/Earnings 50.3x
Price/Sales 5.4x
Price/Book 3.5x
Price/Cash Flow 50.9x
TEV/Sales 5.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact JCR PHARMACEUTICALS CO LTD, please visit www.jcrpharm.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.